Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Eur J Cancer. 2010 May 23;46(11):2097–2103. doi: 10.1016/j.ejca.2010.04.022

Fig 2.

Fig 2

The variance in SN-38 glucuronide formation in the absence or presence of 0.5 μM erlotinib in the whole 52 Caucasian liver microsomes and among different UGT1A1*28 genotypes (A), as well as inhibition potential of erlotinib (B) in 52 Caucasian liver microsomes. Incubations were performed as described under Materials and Methods. Data represent means of duplicate determinations.